Korro to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Korro (Nasdaq: KRRO) announced that President & CEO Ram Aiyar will participate in two investor conferences: the Citi 2026 Biopharma Back to School Summit on September 9, 2026 at 8:40 AM ET, and the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 1:00 PM ET. Both appearances will be fireside chats moderated by biotech equity research analysts. Korro is a Cambridge, Massachusetts-based biopharmaceutical company developing RNA-editing genetic medicines using its OPERA platform and plans to use its Investor Relations website and social channels for Regulation FD-compliant disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:

Citi 2026 Biopharma Back to School Summit
Format: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, Citi
Date: September 9^th, 2026
Time: 8:40 AM ET

2026 Cantor Global Healthcare Conference
Format: Fireside chat moderated by Steve Seedhouse, Biotechnology Equity Analyst, Cantor
Date: September 10^th, 2026
Time: 1:00 PM ET

About Korro

Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.  As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Korro Bio Contact Information

Investor & Media Contact
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

FAQ

What investor conferences will Korro (NASDAQ: KRRO) participate in during September 2026?

Korro will participate in the Citi 2026 Biopharma Back to School Summit and the 2026 Cantor Global Healthcare Conference. According to Korro, both events feature fireside chats with President & CEO Ram Aiyar moderated by biotech equity research analysts.

When is Korro (KRRO) presenting at the Citi 2026 Biopharma Back to School Summit?

Korro will appear at the Citi 2026 Biopharma Back to School Summit on September 9, 2026 at 8:40 AM ET. According to Korro, the session will be a fireside chat moderated by Citi biotech equity research director Yigal Nochomovitz.

When is Korro (KRRO) scheduled to speak at the 2026 Cantor Global Healthcare Conference?

Korro is scheduled for a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 1:00 PM ET. According to Korro, the discussion will be moderated by Cantor biotechnology equity analyst Steve Seedhouse.

What does Korro Bio (NASDAQ: KRRO) focus on in its OPERA RNA-editing platform?

Korro focuses on its OPERA platform, which delivers RNA-editing oligonucleotides to modify native mRNA and generate therapeutic proteins. According to Korro, OPERA integrates ADAR biology, machine learning-optimized REOs, linker chemistry, and tissue-specific delivery to create differentiated genetic medicine programs.

How does Korro (KRRO) plan to deliver its RNA-editing medicines to patients?

Korro plans to use REO-based medicines delivered via precedented modalities, including GalNAc-conjugated subcutaneous administration. According to Korro, this leverages existing manufacturing expertise and established regulatory pathways used by approved oligonucleotide medicines to advance its OPERA-based therapies.

Where can investors follow Korro (KRRO) for material company updates and Regulation FD disclosures?

Investors should monitor Korro’s Investor Relations website and follow the company on LinkedIn and X (Twitter). According to Korro, these channels, along with press releases, SEC filings, calls, and webcasts, will be used for material disclosures.